A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.
<h4>Background</h4>The World Health Organization recommends at least 3 annual antibiotic mass drug administrations (MDA) where the prevalence of trachoma is > 10% in children ages 1-9 years, with coverage at least at 80%. However, the additional value of higher coverage targeted at ch...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0002415&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850161463085236224 |
|---|---|
| author | Sheila K West Robin Bailey Beatriz Munoz Tansy Edwards Harran Mkocha Charlotte Gaydos Thomas Lietman Travis Porco David Mabey Thomas C Quinn |
| author_facet | Sheila K West Robin Bailey Beatriz Munoz Tansy Edwards Harran Mkocha Charlotte Gaydos Thomas Lietman Travis Porco David Mabey Thomas C Quinn |
| author_sort | Sheila K West |
| collection | DOAJ |
| description | <h4>Background</h4>The World Health Organization recommends at least 3 annual antibiotic mass drug administrations (MDA) where the prevalence of trachoma is > 10% in children ages 1-9 years, with coverage at least at 80%. However, the additional value of higher coverage targeted at children with multiple rounds is unknown.<h4>Trial design</h4>2 × 2 factorial community randomized, double blind, trial.<h4>Trial methods</h4>32 communities with prevalence of trachoma ≥ 20% were randomized to: annual MDA aiming for coverage of children between 80%-90% (usual target) versus aiming for coverag e> 90% (enhanced target); and to: MDA for three years versus a rule of cessation of MDA early if the estimated prevalence of ocular C. trachomatis infection was less than 5%. The primary outcome was the community prevalence of infection with C. trachomatis at 36 months.<h4>Results</h4>Over the trial's course, no community met the MDA cessation rule, so all communities had the full 3 rounds of MDA. At 36 months, there was no significant difference in the prevalence of infection, 4.0 versus 5.4 (mean adjusted difference = 1.4%, 95% CI = -1.0% to 3.8%), nor in the prevalence of trachoma, 6.1 versus 9.0 (mean adjusted difference = 2.6%, 95% CI = -0.3% to 5.3%) comparing the usual target to the enhanced target group. There was no difference if analyzed using coverage as a continuous variable.<h4>Conclusion</h4>In communities that had pre-treatment prevalence of follicular trachoma of 20% or greater, there is no evidence that MDA can be stopped before 3 annual rounds, even with high coverage. Increasing coverage in children above 90% does not appear to confer additional benefit. |
| format | Article |
| id | doaj-art-ad097b58f9bf40e0a76ee2e0083a20b9 |
| institution | OA Journals |
| issn | 1935-2727 1935-2735 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj-art-ad097b58f9bf40e0a76ee2e0083a20b92025-08-20T02:22:49ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352013-01-0178e241510.1371/journal.pntd.0002415A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.Sheila K WestRobin BaileyBeatriz MunozTansy EdwardsHarran MkochaCharlotte GaydosThomas LietmanTravis PorcoDavid MabeyThomas C Quinn<h4>Background</h4>The World Health Organization recommends at least 3 annual antibiotic mass drug administrations (MDA) where the prevalence of trachoma is > 10% in children ages 1-9 years, with coverage at least at 80%. However, the additional value of higher coverage targeted at children with multiple rounds is unknown.<h4>Trial design</h4>2 × 2 factorial community randomized, double blind, trial.<h4>Trial methods</h4>32 communities with prevalence of trachoma ≥ 20% were randomized to: annual MDA aiming for coverage of children between 80%-90% (usual target) versus aiming for coverag e> 90% (enhanced target); and to: MDA for three years versus a rule of cessation of MDA early if the estimated prevalence of ocular C. trachomatis infection was less than 5%. The primary outcome was the community prevalence of infection with C. trachomatis at 36 months.<h4>Results</h4>Over the trial's course, no community met the MDA cessation rule, so all communities had the full 3 rounds of MDA. At 36 months, there was no significant difference in the prevalence of infection, 4.0 versus 5.4 (mean adjusted difference = 1.4%, 95% CI = -1.0% to 3.8%), nor in the prevalence of trachoma, 6.1 versus 9.0 (mean adjusted difference = 2.6%, 95% CI = -0.3% to 5.3%) comparing the usual target to the enhanced target group. There was no difference if analyzed using coverage as a continuous variable.<h4>Conclusion</h4>In communities that had pre-treatment prevalence of follicular trachoma of 20% or greater, there is no evidence that MDA can be stopped before 3 annual rounds, even with high coverage. Increasing coverage in children above 90% does not appear to confer additional benefit.https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0002415&type=printable |
| spellingShingle | Sheila K West Robin Bailey Beatriz Munoz Tansy Edwards Harran Mkocha Charlotte Gaydos Thomas Lietman Travis Porco David Mabey Thomas C Quinn A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. PLoS Neglected Tropical Diseases |
| title | A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. |
| title_full | A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. |
| title_fullStr | A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. |
| title_full_unstemmed | A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. |
| title_short | A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. |
| title_sort | randomized trial of two coverage targets for mass treatment with azithromycin for trachoma |
| url | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0002415&type=printable |
| work_keys_str_mv | AT sheilakwest arandomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT robinbailey arandomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT beatrizmunoz arandomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT tansyedwards arandomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT harranmkocha arandomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT charlottegaydos arandomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT thomaslietman arandomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT travisporco arandomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT davidmabey arandomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT thomascquinn arandomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT sheilakwest randomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT robinbailey randomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT beatrizmunoz randomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT tansyedwards randomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT harranmkocha randomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT charlottegaydos randomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT thomaslietman randomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT travisporco randomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT davidmabey randomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma AT thomascquinn randomizedtrialoftwocoveragetargetsformasstreatmentwithazithromycinfortrachoma |